A Study of TAS1440 With ATRA in Subjects With r/r AML
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, 2-part, Phase 1 study to assess the safety, pharmacokinetics,
pharmacodynamics, and preliminary clinical activity of TAS1440 administered as a single agent
and in combination with all-trans retinoic acid (ATRA) in participants with acute myeloid
leukemia (AML) who have relapsed or are refractory (r/r) to prior treatment. The study
duration is expected to be approximately 30 months.